Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period

Arthritis Care and Research

Volumn 64, Issue 4, 2012, Pages 511-518

  Steiman, Amanda J ^a   Gladman, Dafna D ^a   Ibañez, Dominique ^b   Urowitz, Murray B ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; INCIDENCE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PROTEINURIA; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; ANTIBODIES, ANTI-IDIOTYPIC; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CREATININE; DNA; FEMALE; HUMANS; INCIDENCE; KIDNEY DISEASES; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PROGNOSIS; REMISSION, SPONTANEOUS; TIME FACTORS; YOUNG ADULT;

EID: 84859758878     PISSN: 00043591     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21568     Document Type: Article

References (51)

1. Forger F, Matthias T, Oppermann M, Becker H, Helmke K. Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus 2004;13:36-44. (Pubitemid 38129349)
2. Isenberg DA, Manson JJ, Ehrenstein MR, Rahman A. Fifty years of anti-dsDNA antibodies: are we approaching journey's end? Rheumatology (Oxford) 2007;46:1052-6. (Pubitemid 47050602)
3. Rahman A, Isenberg DA. Systemic lupus erythematosus. New Engl J Med 2008;358:929-39. (Pubitemid 351397092)
4. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25: 1271-7. (Pubitemid 13221242)
5. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
6. Koffler D, Schur PH, Kunkel HG. Immunological studies concerning the nephritis of systemic lupus erythematosus. J Exp Med 1967;126:607-24.
7. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticocorticosteroids. Arthritis Rheum 2000;43:1801-8. (Pubitemid 30642567)
8. Swaak AJ, Groenwold J, Aarden LA, Statius van Eps LW, Feltkamp TE. Prognostic value of anti-dsDNA in SLE. Ann Rheum Dis 1982;41:388-95. (Pubitemid 12038906)
9. Tseng CE, Buyon JP, Kim M, Belmont HM, Mackay M, Diamond B, et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebocontrolled trial. Arthritis Rheum 2006;54:3623-32. (Pubitemid 44737174)
10. Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 2006;85: 147-56. (Pubitemid 43833013)
11. Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med 1979;66:210-5. (Pubitemid 9098787)
12. Gladman DD, Urowitz MB. The SLICC/ACR damage index: progress report and experience in the field. Lupus 1999;8: 632-7. (Pubitemid 29520529)
13. Becker-Merok A, Nossent HC. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol 2006;33:1570-7. (Pubitemid 44168829)
14. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9. (Pubitemid 26085211)
15. Sitia S, Ateni F, Sarzi-Puttini P, Di Bello V, Tomasoni L, Delfino L, et al. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun Rev 2009;8:281-6.
16. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957-63. (Pubitemid 37553561)
17. Thomas GN, Tam LS, Tomlinson B, Li EK. Accelerated atherosclerosis in patients with systemic lupus erythematosus: a review of the causes and possible prevention. Hong Kong Med J 2002;8:26-32.
18. Ibanez D, Urowitz MB, Gladman DD. Disease activity over time (adjusted mean SLEDAI) predicts mortality and damage in SLE. J Rheumatol 2005;32:824-7. (Pubitemid 40676490)
19. Swaak AJ, van den Brink HG, Smeenk RJ, Manger K, Kalden JR, Tosi S, et al. Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation. Rheumatology (Oxford) 1999;38:953-8. (Pubitemid 29505076)
20. Urowitz MB, Gladman DD. Contributions of observational cohort studies in systemic lupus erythematosus: the University of Toronto Lupus Clinic Experience. Rheum Dis Clin North Am 2005;31:211-21. (Pubitemid 40732485)
21. Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1955-9. (Pubitemid 37075543)
22. Wold RT, Young FE, Tan EM, Farr RS. Deoxyribonucleic acid antibody: a method to detect its primary interaction with deoxyribonucleic acid. Science 1968;161:806-7.
23. Whicher JT, Price CP, Spencer K. Immunonephelometric and immunoturbidimetric assays for proteins. Crit Rev Clin Lab Sci 1983;18:213-60.
24. Steiman AJ, Gladman DD, Ibanez D, Urowitz MB. Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J Rheumatol 2010;37: 1822-7.
25. Szekanecz Z, Shoenfeld Y. Lupus and cardiovascular disease: the facts. Lupus 2006;15:3-10.
26. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-5.
27. Lee SS, Singh S, Link K, Petri M. High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum 2008; 38:41-54.
28. MacGowan JR, Ellis S, Griffiths M, Isenberg DA. Retrospective analysis of outcome in a cohort of patients with lupus nephritis treated between 1977 and 1999. Rheumatology (Oxford) 2002;41:981-7.
29. Bastian HM, Roseman JM, McGwin Jr G, Alarcon GS, Friedman AW, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 2002;11:152-60. (Pubitemid 34296930)
30. Van Bavel CC, van der Vlag J, Berden JH. Glomerular binding of anti-dsDNA autoantibodies: the dispute resolved? Kidney Int 2007;71:600-1. (Pubitemid 46494566)
31. Swaak AJ, Aarden LA, Statius van Eps LW, Feltkamp TE. Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum 1979;22:226-35. (Pubitemid 9157358)
32. Swaak AJ, Groenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 1986;45:359-66. (Pubitemid 16121710)
33. Riboldi P, Gerosa M, Moroni G, Radice A, Allegri F, Sinico A, et al. Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus? Autoimmunity 2005;38: 39-45. (Pubitemid 40515002)
34. Lightfoot RW, Hughes GR. Significance of persisting serologic abnormalities in SLE. Arthritis Rheum 1976;19:837-43.
35. Zuniga R, Markowitz GS, Arkachaisri T, Imperatore EA, D'Agati VD, Salmon JE. Identification of IgG subclasses and C-reactive protein in lupus nephritis: the relationship between the composition of immune deposits and Fcγ receptor type IIA alleles. Arthritis Rheum 2003;48:460-70. (Pubitemid 36278015)
36. Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology (Oxford) 2004;43:1555-60. (Pubitemid 39642582)
37. Walz LeBlanc BA, Gladman DD, Urowitz MB. Serologically active clinically quiescent systemic lupus erythematosus: predictors of clinical flares. J Rheumatol 1994;21:2239-41.
38. Bootsma H, Spronk P, Derksen R, de Boer G, Wolters-Dickie H, Hermans J, et al. Prevention of relapse in systemic lupus erythematosus. Lancet 1995;345:1595-9.
39. Ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: a long-term, prospective study. Arthritis Rheum 1990;33:634-43. (Pubitemid 20166564)
40. Ho A, Magder LS, Barr SG, Petri M. Decreases in anti-doublestranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2342-9. (Pubitemid 32977502)
41. Ibanez D, Urowitz MB, Gladman DD. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 2005;32:824-7. (Pubitemid 40676490)
42. Yee CS, Hussein H, Skan J, Bowman S, Situnayake D, Gordon C. Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus. Rheumatology (Oxford) 2003;42:276-9. (Pubitemid 36305614)
43. Prasad R, Ibanez D, Gladman D, Urowitz M. Anti-dsDNA and anti-Sm antibodies do not predict damage in systemic lupus erythematosus. Lupus 2006;15:285-91. (Pubitemid 43828805)
44. Isenberg D. Anti-dsDNA antibodies: still a useful criterion for patients with systemic lupus erythematosus? Lupus 2004;13: 881-5. (Pubitemid 39551627)
45. Mostoslavsky G, Fischel R, Yachimovich N, Yaarkoni Y, Rosenmann E, Monestier M, et al. Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: a case for tissue injury by molecular mimicry. Euro J Immunol 2001; 31:1221-7.
46. Neogi T, Gladman DD, Ibanez D, Urowitz M. Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. J Rheumatol 2006;33:1785-8. (Pubitemid 44373212)
47. Amoura Z, Koutouzov S, Chabre H, Cacoub P, Amoura I, Musset L. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum 2000;43:76-84. (Pubitemid 30368215)
48. Gutierrez-Adrianzen OA, Koutouzov S, Mota RM, das Chagas Medeiros MM, Bach JF, de Holanda Campos H. Diagnostic value of anti-nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti-nucleosome with anti-dsDNA antibodies. J Rheumatol 2006;33:1538-44. (Pubitemid 44168824)
49. Su Y, Jia RL, Han L, Li ZG. Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus. Clin Immunol 2007;122:115-20. (Pubitemid 46026699)
50. Duzgun N, Sahin M, Genc Y, Tutkak H. Antinucleosome antibodies and systemic lupus erythematosus. Ann N Y Acad Sci 2007;1109:421-8. (Pubitemid 47511385)
51. Ng KP, Manson JJ, Rahman A, Isenberg DA. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 2006;55:900-4. (Pubitemid 44917463)